M. Weigel

First-in-human phase I study of ISTH0036, an antisense oligonucleotide selectively targeting transforming growth factor beta 2 (TGF-β2), in subjects with open-angle glaucoma undergoing glaucoma filtration surgery

H. Thieme, N. Pfeiffer, M. Janicot, 2017, PloS one.

Main results of the First-In Human single ascending dose phase I study of ISTH0036, an antisense oligonucleotide selectively targeting transforming growth factor beta 2 (TGF-β2) in glaucoma filtration surgery

H. Thieme, N. Pfeiffer, K. Lorenz, 2017 .

First-inhuman phase I study of ISTH 0036 , an antisense oligonucleotide selectively targeting transforming growth factor beta 2 ( TGF-β 2 ) , in subjects with open-angle glaucoma undergoing glaucoma filtration surgery

H. Thieme, N. Pfeiffer, M. Janicot, 2017 .

Telemetric measurement of intraocular pressure via an implantable pressure sensor - twelve-month results from the ARGOS-02 trial.

H. Thieme, A. Jünemann, N. Plange, 2019, American journal of ophthalmology.